• Scientific rationale

    Breast cancer research has been the frontrunner in many fields of cancer research: epidemiology, life-style and genetic risk factors, secondary prevention, conservative surgery, molecular classification, curative adjuvant therapies, neoadjuvant treatments, targeted agents, survival prolongation in advanced stages. Thanks to this knowledge, today many breast cancers can be prevented, most can be diagnosed at early stages and cured and the minority of patients at advanced stages can still enjoy a significant survival with a reasonable quality of life.
    As a consequence of these major improvements, the bar of research and clinical excellence for breast cancer has raised even more.
    New prognostic and predictive biomarkers are available, need to be validated and to be implemented in trial design and clinical practice. Risk-adapted surgery and radiation therapy allow for less and less invasive procedures. Multiple effective adjuvant therapies in the different molecular breast cancer subtypes, require a more precise definition of risk and predictivity of drug efficacy, to allow for a rational de-escalation or escalation of curative treatments. The impressive advances in the treatment of advanced breast cancers, envisage the possibility of cure with a multimodality approach for some patients and guarantee a prolonged survival for most of them with a rational sequencing of treatments.
    The 20th AIBCC in Padova, will allow to sum up the most recent biological and clinical achievements and to allow an open and friendly discussion of clinical cases among key opinion leaders and participants.

    Visit the website https://meettheprofessor.accmed.org/

  • Programme

    10.30Introduction to the Conference
    Pierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat
    Chairpersons: Maria Vittoria Dieci, Hesham Ahmed Gaballah Elghazaly
    11.00Gene expression tools in early-stage HR+/HER2- breast cancer: questioning the grey areas
    Alberto Zambelli
    11.20The immune system and breast cancer: TNBC and beyond 
    Marleen Kok
    11.40DNA NGS-based biomarkers to inform treatment sequence in advanced breast cancer
    Mafalda Oliveira
    12.00Tackling the biological diversity in HER2-positive breast cancer: clinical implications
    Aleix Prat
    Chairpersons: Jacek Jassem, Eleftherios Mamounas
    14.00Surgery of the axilla: is less always more?
    Oreste Davide Gentilini
    14.20Navigating RT options according to genetic risck profiles
    Philip Poortmans
    14.40Evolving concepts in genetic testing: finding the balance
    Angela Toss
    Chairpersons:Pierfranco Conte, Sibylle Loibl
    15.30Modulation of neoadjuvant and post-neoadjuvant treatment in HER2+ (pert, TDM1, neratinib, trials) 
    Sibylle Loibl
    15.50Modulation of neoadjuvant and post-neoadjuvant treatment in  TNBC (IO, PARPi, capeitabine)
    Pierfranco Conte
    16.10Indication to and modalities of neoadjuvant Tx in HR+HER2- BC 
    Valentina Guarneri
    17.15Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2024 
    17.30Lecture of the Awardee
    Chairpersons: Valentina Guarneri, Aleix Prat
    9.00Enhancing efficacy of hormonal therapy in early breast cancer (bisphosphonates, extended, CDK4/6i, SERDs, PARPi…)
    Stephen Johnston
    9.20Optimizing treatment for small tumors depending on local treatments
    Hope Rugo
    9.40The challenge of lobular breast cancer
    Maria Vittoria Dieci
    10.30Coffee break
    11.00Clinical Multidisciplinary Shooting Session 1 – Early Breast Cancer
    Bettina Borisch, Hesham Ahmed Gaballah Elghazaly, Oreste Davide Gentilini, Jacek Jassem, Sibylle Loibl, Eleftherios Mamounas, Alberto Marchet, Fedro Alessandro Peccatori, Philip Poortmans, Aleix Prat
    Chairpersons: Piefranco Conte, Sandra Swain M.
    13.30HR+ disease
    Current algorithm: Claudio Vernieri
    Adapting the algorithm in a contemporary scenario: Carmen Criscitiello
    14.00HER2+ disease
    Current algorithm: Federica Miglietta
    Treatment sequences in new emerging populations: Sandra Swain
    14.30Triple negative disease
    Current algorithm: Gaia Griguolo
    Treatment sequences in new emerging populations: Hope Rugo
    15.20 Clinical Multidisciplinary Shooting Session 2 – Advanced Breast Cancer
    Pierfranco Conte, Hesham Ahmed Gaballah Elghazaly, Oreste Davide Gentilini, Stephen Johnston, Philip Poortmans, Hope Rugo, Sandra Swain M
    16.40Take home messages and adjourn
    Pierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat

  • Faculty

    Pierfranco Conte VeneziaValentina Guarneri Padova
    Philip Poortmans Wolrijk-antwerp (Belgio)Aleix Prat Barcellona (Spagna)

    Bettina Borisch Geneva (Svizzera)Carmen Criscitiello Milano
    Maria Vittoria Dieci PadovaHesham Ahmed Gaballah Elghazaly Cairo (Egitto)
    Oreste Davide Gentilini MilanoGaia Griguolo Padova
    Jacek Jassem Gdansk (Polonia)Stephen Johnston Londra (Regno Unito)
    Marleen Kok Amsterdam (Paesi Bassi)Sibylle Loibl Francoforte (Germania)
    Eleftherios Mamounas Orlando - Florida (Stati Uniti D'America)Alberto Marchet Padova
    Federica Miglietta PadovaMafalda Oliveira Barcellona (Spagna)
    Fedro Alessandro Peccatori MilanoHope Rugo San Francisco (Stati Uniti D'America)
    Sandra Swain M Washington (Stati Uniti D'America)Angela Toss Modena
    Claudio Vernieri MilanoAlberto Zambelli Rozzano (MI)

  • How to participate the meeting

    Enrollment in the course can only be done through the online procedure, no new registrations will be accepted at the congress venue.

  • Registration

    Participation registration fees

    • Quota di partecipazione intera € 120.00
    • Quota di iscrizione per specializzandi € 80.00
    • Quota di iscrizione soci aiom € 80.00

    For eligibility criteria and other information on reduced fees (if applicable), contact info.bologna@accmed.org.

    To participate in the event, it is necessary to complete the registration procedure (including payment of the applicable fee) by 19/10/2024. Payment can be made online exclusively with Credit Cards or Paypal.

    If the minimum number of participants is not reached, the Academy reserves the right to cancel the activity. In this case, Accademia will proceed with the appropriate communication and full refund of the participation fees.

    In case of withdrawal, please inform AccMed promptly. If the waiver occurs within the 10th day prior to the start date of the event, the amount paid will be returned with the deduction of 30%. If the waiver occurs after that deadline, no reimbursement will be provided.

  • CME Instructions

    To obtain CME credits, users must meet the following requirements:

    1. Their declared profession/specialization must correspond to those accredited for CME.
    2. They must attend at least 90% of the course.
    3. They must complete the online meeting evaluation form.
    4. They must pass the learning assessment test with at least 75% correct answers. Only one attempt is allowed.

    The learning assessment test and meeting evaluation form must be submitted within three days of the event.

    Please note that in order to access the learning assessment test, users must (A) register at the course venue and (B) submit the online meeting evaluation form.

    Certificate of attendance 
    To download the certificate of attendance, users must have registered at the course venue.
    If their attendance is less than 75% of the stated duration, the certificate will reflect the percentage of attendance.
    We strongly encourage users to keep track of their personal badge and the badge recordings by the AccMed personnel, it is users' responsibility to have their attendance recorded accurately.

  • Training objective

    Contenuti tecnico-professionali (conoscenze e competenze) specifici di ciascuna professione, di ciascuna specializzazione e di ciascuna attività ultraspecialistica, ivi incluse le malattie rare e la medicina di genere